GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neoleukin Therapeutics Inc (NAS:NLTX) » Definitions » Intrinsic Value: Projected FCF

Neoleukin Therapeutics (Neoleukin Therapeutics) Intrinsic Value: Projected FCF : $-97.11 (As of May. 02, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Neoleukin Therapeutics Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-05-02), Neoleukin Therapeutics's Intrinsic Value: Projected FCF is $-97.11. The stock price of Neoleukin Therapeutics is $3.49. Therefore, Neoleukin Therapeutics's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Neoleukin Therapeutics's Intrinsic Value: Projected FCF or its related term are showing as below:

NLTX's Price-to-Projected-FCF is not ranked *
in the Biotechnology industry.
Industry Median: 2.355
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Neoleukin Therapeutics Intrinsic Value: Projected FCF Historical Data

The historical data trend for Neoleukin Therapeutics's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neoleukin Therapeutics Intrinsic Value: Projected FCF Chart

Neoleukin Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -149.27 -79.05 -42.70 -71.72 -97.06

Neoleukin Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -92.00 -97.06 -102.95 -98.20 -97.11

Competitive Comparison of Neoleukin Therapeutics's Intrinsic Value: Projected FCF

For the Biotechnology subindustry, Neoleukin Therapeutics's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neoleukin Therapeutics's Price-to-Projected-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neoleukin Therapeutics's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Neoleukin Therapeutics's Price-to-Projected-FCF falls into.



Neoleukin Therapeutics Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)


Add all the Free Cash Flow together and divide 6 will get Neoleukin Therapeutics's Free Cash Flow(6 year avg) = $-34.63.

Neoleukin Therapeutics's Intrinsic Value: Projected FCF for today is calculated as

Intrinsic Value: Projected FCF=(Growth Multiple*Free Cash Flow (6 year avg)+Total Stockholders Equity (Sep23)*0.8)/Shares Outstanding (Diluted Average)
=(9.5203515959648*-34.62896+75.235*0.8)/2.775
=-97.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Neoleukin Therapeutics  (NAS:NLTX) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Neoleukin Therapeutics's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=3.49/-97.114189045983
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Neoleukin Therapeutics Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Neoleukin Therapeutics's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Neoleukin Therapeutics (Neoleukin Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
188 East Blaine Street, Suite 450, Seattle, WA, USA, 98102
Neoleukin Therapeutics Inc operates as a biopharmaceutical company. The firm generates immunotherapies using de novo protein design technology. It uses computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefits over native proteins to treat serious diseases, including cancer, inflammatory, and autoimmune disorders. Its product line comprises NL-201, which is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding.
Executives
Baker Bros. Advisors Lp 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Sean Michael Smith officer: Principal Accounting Officer C/O NEOLEUKIN THERAPEUTICS, INC., 188 E. BLAINE STREET, SUITE 450, SEATTLE WA 98102
Priti Patel officer: Chief Medical Officer C/O NEOLEUKIN THERAPEUTICS, INC., 188 EAST BLAINE STREET, #450, SEATTLE WA 98102
Erin Lavelle director C/O ALDER BIOPHARMACEUTICALS, INC., 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
Donna Cochener officer: General Counsel, SVP Legal C/O NEOLEUKIN THERAPEUTICS, INC., 188 EAST BLAINE STREET, SUITE 450, SEATTLE WA 98102
Rohan Palekar director 201 SPEAR STREET, THIRD FLOOR, SAN FRANCISCO CA 94105
Jonathan G Drachman director, officer: See Remarks 21823 30TH DRIVE SE, BOTHELL WA 98021
Carl Walkey officer: Senior Vice President C/O NEOLEUKIN THERAPEUTICS, INC., 360-1616 EASTLAKE AVENUE EAST, SEATTLE WA 98102
Robert Ho officer: Chief Financial Officer 360-1616 EASTLAKE AVENUE EAST, SEATTLE WA 98102
Holly Vance officer: General Counsel C/O NEOLEUKIN THERAPEUTICS, INC., 360-1616 EASTLAKE AVENUE E., SEATTLE WA 98102
Martin Babler director C/O INFINITY PHARMACEUTICALS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Erin M. Lavelle director 360-1616 EASTLAKE AVENUE EAST, SEATTLE WA 98102
Redmile Group, Llc 10 percent owner ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
Jeremy Green 10 percent owner 45 W. 27TH STREET, FLOOR 11, NEW YORK NY 10001
Sarah B. Noonberg director 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080

Neoleukin Therapeutics (Neoleukin Therapeutics) Headlines